New research findings increase understanding of how Wnt5a signaling inhibits movement and migration of breast cancer cells
A scientific article describing in-depth knowledge of how Wnt5a signaling inhibits breast cancer cell movement and migration has been published online in the journal Oncotarget by WntResearch’s Chief Scientific Officer, Professor Tommy Andersson, together with his research group at Lund University.
The scientific article describes preclinical experiments where Wnt5a signaling resulted in a normalization of tumor cell metabolism, from being lactate forming to be non-lactate forming. This metabolic change is a prerequisite for Wnt5a signaling to be able to counteract breast cancer cell mobility and invasiveness.
Further, the research reveals that WntResearch’s drug candidate Foxy-5 inhibits breast cancer cell movement and invasiveness even in a high lactate concentration environment. This finding implicate that Foxy-5 has therapeutic potential even if a tumor or its surrounding connective tissue forms a high local concentration of lactate, which is often associated with aggressive disease.
The scientific article can be accessed via the link below:
For further information, please contact:
Henrik Lawaetz, CEO
Phone: +46 72 702 4694
The information was submitted for publication, through the agency of the contact person set out above, at 09:00 CET on April 21, 2017.
WntResearch is developing a new type of cancer treatment based on pioneering research, which shows that the endogenous protein Wnt-5a plays a crucial role for tumor cells’ ability to relocate and spread inside the body. Most patients that die of cancer do so not due to the primary tumor, but due to metastases and the need for a specific treatment to counteract metastasis is therefore in high demand.
WntResearch’s most advanced drug candidate Foxy-5 has in preclinical tests been shown to reduce tumor cells’ mobility and thereby counteract the occurrence of metastasis. The results from a completed phase 1 study show a favorable security profile and pharmacokinetics as well as early indications of biological activity. A phase 1b study is currently ongoing in patients with cancer in colon, prostate and breast. WntResearch is a public company listed at AktieTorget in Stockholm, Sweden. For further information: www.wntresearch.com